Autopsy report · NCT03367195

Efficacy and Safety of DLBS2411 in the Management of GERD

“Very low recruitment rate. The Study Site classifies as tertiary referral hospital. Therefore, GERD Patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 32 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Dexa Medica Group

Sponsor type

Industry

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

Omeprazole; DLBS2411; Placebo capsule of Omeprazole; Placebo caplet of DLBS2411

Participants

32

Sites

5

Countries

Indonesia

Trials that died the same way

• Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
  “Less patients than expected for inclusion, therefore recruitment is too low” (61% match in meaning)
• Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes
  “Lack of patients with recruitment criteria” (60% match in meaning)
• The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions
  “Due to low patient recruitment” (60% match in meaning)
• Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome
  “Poor study patient recruitment” (59% match in meaning)
• Effect of Semiconductor Embedded Therapeutic Gloves for Hand Osteoarthritis
  “Not enough patients interested at the site” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.